Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia’s GBMA Working To Address Coronavirus Risks

Consumers Urged Not To ‘Panic Purchase’ And Stockpile Drugs

Executive Summary

Australia’s GBMA off-patent industry association says its members are working to minimize the effects of coronavirus, amid reports of drug shortages and empty pharmacy shelves.

You may also be interested in...



Australia Relaxes Competition Rules To Facilitate Coronavirus Response

Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

IGBA Joins Fight The Fakes Alliance

As the Fight The Fakes Alliance holds its fifth annual “Fight The Fakes Week,” the IGBA has signed to become a new member of the association as it calls for fresh action to prevent falsified medicines from reaching patients.

Neuraxpharm Expands European Reach With Dutch Operation

Neuraxpharm has made its latest move into a new European market, this time opening up a new unit in the Netherlands that will be led by the firm’s German head Philipp Pohoralek as country manager.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel